Weight-loss jabs could almost halve the risk of obesity-related cancers, a landmark study suggests.
Cancer experts said the findings were “transformational” and could herald a “whole new era of preventive cancer medicine”.
Obesity is associated with 13 different cancers. While losing weight reduces that risk, scientists have calculated weight-loss injections have a bigger protective effect over and above shedding the kilos.
Researchers in Israel studied 6,000 adults with no prior history of cancer, who either underwent bariatric surgery or took glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide (Saxenda), exenatide (Byetta) or dulaglutide (Trulicity). The drugs work by mimicking the GLP-1 hormone in the body, which lowers blood sugar levels and makes people feel fuller for longer.
